BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21337044)

  • 1. Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer.
    Lesport E; Baudhuin J; Sousa S; LeMaoult J; Zamborlini A; Rouas-Freiss N; Carosella ED; Favier B
    Cell Mol Life Sci; 2011 Oct; 68(20):3385-99. PubMed ID: 21337044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j.
    Morel E; Bellón T
    J Immunol; 2008 Aug; 181(4):2368-81. PubMed ID: 18684926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
    Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
    J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-G modulates immune responses by diverse receptor interactions.
    Hofmeister V; Weiss EH
    Semin Cancer Biol; 2003 Oct; 13(5):317-23. PubMed ID: 14708711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Leukocyte Antigen-G Inhibits the Anti-Tumor Effect of Natural Killer Cells via Immunoglobulin-Like Transcript 2 in Gastric Cancer.
    Wan R; Wang ZW; Li H; Peng XD; Liu GY; Ou JM; Cheng AQ
    Cell Physiol Biochem; 2017; 44(5):1828-1841. PubMed ID: 29224003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
    Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
    J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of cytolytic functions of human Vδ2-γ T lymphocytes through engagement of ILT2 expressed by tumor target cells.
    Harly C; Peyrat MA; Netzer S; Déchanet-Merville J; Bonneville M; Scotet E
    Blood; 2011 Mar; 117(10):2864-73. PubMed ID: 21233315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse.
    Favier B; Lemaoult J; Lesport E; Carosella ED
    FASEB J; 2010 Mar; 24(3):689-99. PubMed ID: 19841038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble HLA-G inhibits myeloid dendritic cell function in HIV-1 infection by interacting with leukocyte immunoglobulin-like receptor B2.
    Huang J; Burke P; Yang Y; Seiss K; Beamon J; Cung T; Toth I; Pereyra F; Lichterfeld M; Yu XG
    J Virol; 2010 Oct; 84(20):10784-91. PubMed ID: 20702625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.
    Malmberg KJ; Levitsky V; Norell H; de Matos CT; Carlsten M; Schedvins K; Rabbani H; Moretta A; Söderström K; Levitskaya J; Kiessling R
    J Clin Invest; 2002 Nov; 110(10):1515-23. PubMed ID: 12438449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
    Avril T; Saikali S; Vauleon E; Jary A; Hamlat A; De Tayrac M; Mosser J; Quillien V
    J Neuroimmunol; 2010 Aug; 225(1-2):22-33. PubMed ID: 20493562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions.
    Saverino D; Fabbi M; Ghiotto F; Merlo A; Bruno S; Zarcone D; Tenca C; Tiso M; Santoro G; Anastasi G; Cosman D; Grossi CE; Ciccone E
    J Immunol; 2000 Oct; 165(7):3742-55. PubMed ID: 11034379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
    Xu Y; Xiang Z; Alnaggar M; Kouakanou L; Li J; He J; Yang J; Hu Y; Chen Y; Lin L; Hao J; Li J; Chen J; Li M; Wu Q; Peters C; Zhou Q; Li J; Liang Y; Wang X; Han B; Ma M; Kabelitz D; Xu K; Tu W; Wu Y; Yin Z
    Cell Mol Immunol; 2021 Feb; 18(2):427-439. PubMed ID: 32939032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma.
    LeMay LG; Kan-Mitchell J; Goedegebuure P; Harel W; Mitchell MS
    Cancer Immunol Immunother; 1993 Aug; 37(3):187-94. PubMed ID: 8101473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Killer Ig-like receptor 2DL4 does not mediate NK cell IFN-γ responses to soluble HLA-G preparations.
    Le Page ME; Goodridge JP; John E; Christiansen FT; Witt CS
    J Immunol; 2014 Jan; 192(2):732-40. PubMed ID: 24337374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting HLA-G restores IFN-γ and TNF-α producing T cell in pleural Tuberculosis.
    Saurabh A; Chakraborty S; Kumar P; Mohan A; Bhatnagar AK; Rishi N; Mitra DK
    Tuberculosis (Edinb); 2018 Mar; 109():69-79. PubMed ID: 29559123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells.
    Selmani Z; Naji A; Zidi I; Favier B; Gaiffe E; Obert L; Borg C; Saas P; Tiberghien P; Rouas-Freiss N; Carosella ED; Deschaseaux F
    Stem Cells; 2008 Jan; 26(1):212-22. PubMed ID: 17932417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
    Cabillic F; Toutirais O; Lavoué V; de La Pintière CT; Daniel P; Rioux-Leclerc N; Turlin B; Mönkkönen H; Mönkkönen J; Boudjema K; Catros V; Bouet-Toussaint F
    Cancer Immunol Immunother; 2010 Nov; 59(11):1611-9. PubMed ID: 20582413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition.
    Riteau B; Menier C; Khalil-Daher I; Martinozzi S; Pla M; Dausset J; Carosella ED; Rouas-Freiss N
    Int Immunol; 2001 Feb; 13(2):193-201. PubMed ID: 11157852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition of nonclassical HLA class I antigens by gamma delta T cells during pregnancy.
    Barakonyi A; Kovacs KT; Miko E; Szereday L; Varga P; Szekeres-Bartho J
    J Immunol; 2002 Mar; 168(6):2683-8. PubMed ID: 11884433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.